These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 19080742)
21. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma]. Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643 [No Abstract] [Full Text] [Related]
22. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756 [TBL] [Abstract][Full Text] [Related]
23. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis. Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012 [TBL] [Abstract][Full Text] [Related]
24. The significance of MGMT methylation in Glioblastoma Multiforme prognosis. Rao AM; Quddusi A; Shamim MS J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322 [TBL] [Abstract][Full Text] [Related]
25. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
26. Treatment considerations for MGMT-unmethylated glioblastoma. Taylor JW; Schiff D Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859 [TBL] [Abstract][Full Text] [Related]
27. Prime time for molecular marker diagnostics in neuro-oncology. Weller M; Stupp R Curr Opin Neurol; 2012 Dec; 25(6):743-4. PubMed ID: 23041956 [No Abstract] [Full Text] [Related]
28. MGMT methylation in glioblastoma: tale of the tail. Shah N; Schroeder B; Cobbs C Neuro Oncol; 2015 Jan; 17(1):167-8. PubMed ID: 25395464 [No Abstract] [Full Text] [Related]
29. High density DNA methylation array is a reliable alternative for PCR-based analysis of the MGMT promoter methylation status in glioblastoma. Braczynski AK; Capper D; Jones DTW; Schittenhelm J; Stichel D; von Deimling A; Harter PN; Mittelbronn M Pathol Res Pract; 2020 Jan; 216(1):152728. PubMed ID: 31784096 [TBL] [Abstract][Full Text] [Related]
30. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study. Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343 [TBL] [Abstract][Full Text] [Related]
31. Glioblastoma Recurrence and the Role of O Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983 [TBL] [Abstract][Full Text] [Related]
32. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo. Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701 [TBL] [Abstract][Full Text] [Related]
33. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Binabaj MM; Bahrami A; ShahidSales S; Joodi M; Joudi Mashhad M; Hassanian SM; Anvari K; Avan A J Cell Physiol; 2018 Jan; 233(1):378-386. PubMed ID: 28266716 [TBL] [Abstract][Full Text] [Related]
34. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Costa BM; Smith JS; Chen Y; Chen J; Phillips HS; Aldape KD; Zardo G; Nigro J; James CD; Fridlyand J; Reis RM; Costello JF Cancer Res; 2010 Jan; 70(2):453-62. PubMed ID: 20068170 [TBL] [Abstract][Full Text] [Related]
35. MGMT Status as a Clinical Biomarker in Glioblastoma. Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734 [TBL] [Abstract][Full Text] [Related]
36. The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. Zhao H; Wang S; Song C; Zha Y; Li L World J Surg Oncol; 2016 Oct; 14(1):261. PubMed ID: 27733166 [TBL] [Abstract][Full Text] [Related]
37. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival. Shu C; Wang Q; Yan X; Wang J Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907 [TBL] [Abstract][Full Text] [Related]
38. Association between glioblastoma cell-derived vessels and poor prognosis of the patients. Mei X; Chen YS; Zhang QP; Chen FR; Xi SY; Long YK; Zhang J; Cai HP; Ke C; Wang J; Chen ZP Cancer Commun (Lond); 2020 May; 40(5):211-221. PubMed ID: 32359215 [TBL] [Abstract][Full Text] [Related]
39. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M; Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906 [TBL] [Abstract][Full Text] [Related]
40. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Xie H; Tubbs R; Yang B Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]